Bortezomib in combination with dexamethasone for relapsed multiple myeloma.

被引：0
|
作者：
Kropff, MH [1 ]
Bisping, G [1 ]
Wenning, D [1 ]
Berdel, WE [1 ]
Kienast, J [1 ]
机构：
[1] Univ Munster, Dept Med Hematol & Oncol, Munster, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4923
引用
收藏
页码：313B / 313B
页数：1
相关论文
共 50 条
  • [1] Bortezomib in combination with dexamethasone for relapsed multiple myeloma
    Kropff, MH
    Bisping, G
    Wenning, D
    Volpert, S
    Tchinda, J
    Berdel, EW
    Kienast, J
    LEUKEMIA RESEARCH, 2005, 29 (05) : 587 - 590
  • [2] Bendamustine-bortezomib-dexamethasone in relapsed/refractory multiple myeloma.
    Cerchione, Claudio
    Nappi, Davide
    Cangini, Delia
    Ronconi, Sonia
    Ceccolini, Michela
    Musuraca, Gerardo
    Martinelli, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [4] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Phase lb study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma.
    Laubach, Jacob
    Tuchman, Sascha Alexander
    Rosenblatt, Jacalyn
    Redd, Robert
    Colson, Kathleen
    Motta, Ashley
    Fitzpatrick, Kathleen
    Weller, Edie
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Cyclophosphamide, bortezomib, and dexamethasone (CYBORD) treatment for relapsed/refractory multiple myeloma.
    Monge, Jorge
    Kortuem, K. Martin
    Stewart, A. Keith
    Bergsagel, P. Leif
    Mikhael, Joseph
    Reeder, Craig B.
    Mayo, Angela
    Fonseca, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [7] Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma
    Moreau, Philippe
    Facon, Thierry
    Touzeau, Cyrille
    Benboubker, Lotfi
    Delain, Martine
    Badamo-Dotzis, Julie
    Phelps, Charles
    Doty, Christopher
    Smit, Hans
    Fourneau, Nele
    Forslund, Ann
    Hellemans, Peter
    Leleu, Xavier
    LEUKEMIA & LYMPHOMA, 2016, 57 (07) : 1546 - 1559
  • [8] Phase Ib venetoclax combined with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Chanan-Khan, Asher Alban Akmal
    Roberts, Andrew Warwick
    Agarwal, Amit
    Facon, Thierry
    Kumar, Shaji
    Touzeau, Cyrille
    Diehl, Susan
    Cordero, Jaclyn
    Ross, Jeremy A.
    Munasinghe, Wijith
    Zhu, Ming
    Salem, Ahmed H.
    Leverson, Joel
    Maciag, Paulo Cesar
    Verdugo, Maria E.
    Harrison, Simon J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
    Alsina, Melissa
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael S.
    Mukhopadhyay, Sutapa
    Paley, Carole S.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
12345